Westphal Dana, Glitza Oliva Isabella C, Niessner Heike
Department of Dermatology, Carl Gustav Carus Medical Center, Technical University of Dresden, Dresden, Germany.
Center for Regenerative Therapies, Technical University of Dresden, Dresden, Germany.
Cancer. 2017 Jun 1;123(S11):2163-2175. doi: 10.1002/cncr.30594.
Substantial proportions of patients with metastatic melanoma develop brain metastases during the course of their disease, often resulting in significant morbidity and death. Despite recent advances with BRAF/MEK and immune-checkpoint inhibitors in the treatment of patients who have melanoma with extracerebral metastases, patients who have melanoma brain metastases still have poor overall survival, highlighting the need for further therapy options. A deeper understanding of the molecular pathways involved in the development of melanoma brain metastases is required to develop more brain-specific therapies. Here, the authors summarize the currently known preclinical data and describe steps involved in the development of melanoma brain metastases. Only by knowing the molecular background is it possible to design new therapeutic agents that can be used to improve the outcome of patients with melanoma brain metastases. Cancer 2017;123:2163-75. © 2017 American Cancer Society.
相当比例的转移性黑色素瘤患者在疾病过程中会发生脑转移，常常导致严重的发病和死亡。尽管最近BRAF/MEK和免疫检查点抑制剂在治疗伴有脑外转移的黑色素瘤患者方面取得了进展，但患有黑色素瘤脑转移的患者总体生存率仍然很低，这凸显了对进一步治疗方案的需求。需要更深入地了解黑色素瘤脑转移发生过程中涉及的分子途径，以开发更多针对脑部的疗法。在此，作者总结了目前已知的临床前数据，并描述了黑色素瘤脑转移发生的步骤。只有了解分子背景，才有可能设计出新的治疗药物，用于改善黑色素瘤脑转移患者的治疗结果。《癌症》2017年；123:2163 - 2175。©2017美国癌症协会。
